Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Smernice za obravnavo bolnikov s skvamoznoceličnim karcinomom analnega kanala in kože perinealno (analnega roba)
Authors:Oblak, Irena (Author)
Velenik, Vaneja (Author)
Anderluh, Franc (Author)
Skoblar Vidmar, Marija (Author)
But Hadžić, Jasna (Author)
Brecelj, Erik (Author)
Reberšek, Martina (Author)
Jelenc, Franc (Author)
Potrč, Stojan (Author)
Tipology:1.04 - Professional Article
Organisation:Logo OI - Institute of Oncology
Keywords:rak (medicina), debelo črevo, danka
Year of publishing:2013
COBISS_ID:1651323 Link is opened in a new window
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
Note:Soavtorji: V. Velenik, F. Anderluh, M. Skoblar Vidmar, J. But Hadžić, E. Brecelj, M. Reberšek, F. Jelenc, S. Potrč;
Files:.pdf PDF - Presentation file, download (309,75 KB)
Onkološki inštitut
Rights:by Authors
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Title:Guidelines for the management of patients with squamous cell carcinoma of the anal canal and perianal skin (anal margin)
Abstract:Cancer of the anal canal and anal margin is a rare disease. In Slovenia, on average 20 patients are diagnosed with this disease each year, more women than men. However, the incidence has increased in the last year, mainly in young, homosexual men, most probably due to infections with the sexually-transmitted human papillomavirus (HPV) and human immunodeficiency virus (HIV), which are known causal agents of this disease. Cancer of the anal canal and anal margin is primarily a locoregional disease, as distant metastases are found in less than 10% of the patients. Radical radiochemotherapy plays the central role in the treatment of anal canal and anal margin carcinomas with no distant metastases, except in well-differentiated anal margin carcinomas smaller than 2 cm, where local excision is advised. Radical radiochemotherapy provides a complete response in as many as 80-90%, which is reflected also in an excellent treatment outcome with 5-year survival of 80%. Patients clinically staged as cT1-2 stand a 6.5% chance of developing inguinal lymph node metastases, while the likelihood in patients staged as cT3-4 is 16%. Surgery, namely abdominoperineal excision, has a role in the treatment of residual disease after radical radiochemotherapy. In the future, HPV vaccines hold great promise for the prevention of this virus-induced disease.